Open-label Adjunctive Zonisamide for Bipolar Disorder

This study has been terminated.
Sponsor:
Information provided by:
Elan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00047567
First received: October 8, 2002
Last updated: December 10, 2015
Last verified: December 2015

October 8, 2002
December 10, 2015
July 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00047567 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open-label Adjunctive Zonisamide for Bipolar Disorder
Not Provided
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bipolar Disorders
Drug: zonisamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
20
July 2002
Not Provided
  • Bipolar I/II
  • Average intelligence
  • Taking at least one, but no more than two mood stabilizers
Both
6 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00047567
ELN-345-509
Not Provided
Not Provided
Not Provided
Not Provided
Elan Pharmaceuticals
Not Provided
Not Provided
Elan Pharmaceuticals
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP